# A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

> **NCT01557504** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin/metformin XR
- **DRUG:** Placebo
- **DRUG:** Metformin
- **DRUG:** Thyroid hormone

## Key facts

- **NCT ID:** NCT01557504
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-18
- **Primary completion:** 2014-04-29
- **Final completion:** 2014-04-29
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01557504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01557504, "A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01557504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*